Gastric cancer – actual multimodality treatment strategies

• Authors: Hans-Joachim Meyer , Jane Nutzmann , Hansjochen Wilke
• Languages of publication: EN
• Publisher: De Gruyter Open
• Journal: Polish Journal of Surgery
• Year: 2012
• Volume: 84
• Issue: 9
• Pages: 461-469

Dates

published

1 - 10 - 2012

online

23 - 10 - 2012

Contributors

author

Hans-Joachim Meyer

• Department of General and Abdominal Surgery, Metroplitan Clinic in Solingen, Germany

author

Jane Nutzmann

• Department of General and Abdominal Surgery, Metroplitan Clinic in Solingen, Germany

author

Hansjochen Wilke

• Essen Center Clinic, IV Department of Internal Medicine, Oncology and Haematology, Essen, Germany

References

• 1. Kelly JR, Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003; 56: 1-9.[Crossref]
• 2. Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-88.
• 3. Grundmann RT , Hölscher AH, Bembenek A et al.: Diagnostik und Therapie des Magenkarzinoms - Workflow. Zentralbl Chir 2009; 134: 362-74.[Crossref]
• 4. Meyer H-J, Opitz G: Aktuelle chirurgische Therapiestrategien beim Magenkarzinom. Verdauungskrankheiten 2007; 25: 112-21.[Crossref]
• 5. Schuhmacher C, Sendler A, Meyer H-J: Chirurgische Therapie des Magenkarzinoms. Onkologe 2008; 14: 339-49.[Crossref]
• 6. Sant M, Allemani C, Santaquilani M et al.: EUROCARE-4: Survival of cancer patients diagnosed in 1995-1999 - Results and commentary. Eur J Cancer 2009; 45: 931-91.[WoS]
• 7. Hundahl SA , Phillips JL, Menck HR: The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer 2000; 88: 921-32.[Crossref][PubMed]
• 8. Wilke H, Stahl M: Therapie beim Magenkarzinom - Aus onkologischer Sicht. Chirurg 2009; 80: 1023-27.[Crossref]
• 9. Lordick F: Prinzipien der neoadjuvanten Therapie. Chirurg 2009; 80: 1000-05.[Crossref]
• 10. Lordick F, Ott K, Sendler A: Magen- und Adenokarzinome des oesophagogastralen Übergangs - Prinzipien der neoadjuvanten Therapie. Chirurg 2011; 82: 968-73.[Crossref]
• 11. Dikken JL, Mansen EPM, Cats A et al.: Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 2010; 28: 2430-36.[Crossref][PubMed]
• 12. Ott K, Lordick F: Neoadjuvante Therapie im oberen Gastrointestinaltrakt - Magenkarzinom aus chirurgischer Sicht. Chirurg 2009; 80: 1028-34.[Crossref]
• 13. Meyer H-J, Opitz GJ, Wilke H: Magenkarzinom. Allgemein- und Viszeralchirurgie up2date 2010; 6: 363-85.
• 14. Meyer H-J, Wilke H: Treatment strategies in gastric cancer. Dtsch Arztebl Int 2011; 108: 698-706.[PubMed]
• 15. Möhler M, Al-Batran SE , Andus T et al.: German S3-Guideline “Diagnosis and Treatment of Esophagogastric Cancer. Z Gastroenterol 2011; 49: 461-31.
• 16. Jaworski R, Bollschweiler E, Hölscher AH et al.: Prognostic relevance of demographics and surgical practice for patients with gastric cancer in two centers: in Poland versus Germany. Gastric Cancer 2011; 14: 234-41.[WoS][Crossref]
• 17. Englisch-Fritz Ch, Hünerbein M, Porschen R: Diagnostik beim Magenkarzinom. Onkologe 2008; 14: 332-38.
• 18. Rabenstein T, Ell C, Feussner H: Endoskopische Resektion und minimal-invasive Verfahren beim Magenkarzinom. Onkologe 2008; 14: 350-61.[Crossref]
• 19. Gotoda T, Yanagisawa A, Sasako M et al.: Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000; 3: 219-25.[Crossref]
• 20. Kwee RM , Kwee TC : Imaging in local staging of gastric cancer: A systematic review. J Clin Oncol 2007; 25: 2107-16.[Crossref][PubMed]
• 21. Beer AJ, Wieder HA, Lordick F et al.: Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. Radiology 2006; 239: 472-80.
• 22. Feussner H, Härtl F: Staginglaparoskopie in der Onkologie. Chirurg 2006; 77: 971-80.[Crossref]
• 23. Gemmill EH, McCulloch P: Systematic review of minimally invasive resection for gastro-oesophageal cancer. Br J Surg 2007; 94: 1461-67.[PubMed][Crossref]
• 24. Bozzetti F, Marubini E, Bonfanti G et al.: Total versus subtotal gastrectomy: Surgical morbidity and mortality rates in a multicenter Italian randomized trail. The Italian Gastrointestinal Tumor Study Group. Ann Surg 1997; 226: 613-20.[Crossref]
• 25. Gouzi JL, Huguier M, Fagniez PL et al.: Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 1989; 209: 162-67.[Crossref]
• 26. Hermanek P: Differenziertes chirurgisches Vorgehen bei der kurativen Therapie des Magenkarzinoms. Leber Magen Darm 1996; 26: 64-72.
• 27. Bonenkamp JJ, Hermans J, Sasako M et al.: Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908-14.[Crossref]
• 28. Cuschieri A, Weeden S, Fielding J et al.: Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-30.[Crossref]
• 29. Hartgrink HH, Jansen EPM, von Grieken NCT et al.: Gastric Cancer. Lancet 2009; 374: 477-490.
• 30. Songun I, Putter H, Meershoek-Klein Kranenbarg E et al.: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-49.[WoS][Crossref]
• 31. Meyer H-J, Wilke H: Aktueller Stand multimodaler Therapiekonzepte beim Magenkarzinom. Viszeralchirurgie 2001; 36: 12-19.[Crossref]
• 32. The GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group: Benefit of adjuvant chemotherapy for resectable gastric cancer. JAMA 2010; 303: 1729-37.
• 33. Macdonald JS, Smalley SR , Benedetti J et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-30.
• 34. Macdonald JS, Benedetti J, Smalley S et al.: Chemoradiation of resected gastric cancer: A 10-year follow-up to the phase III trial INT0116 (SWOG 9008). J Clin Oncol 2009, Suppl 27 (Abstract 4515).
• 35. Wilke H, Willich N, Meyer H-J et al.: Neoadjuvante und perioperative Therapie des Magenkarzinoms. Onkologe 2008; 14: 370-80.[Crossref]
• 36. Wilke H, Preusser P, Fink U et al.: Preoperative chemotherapy in locally advanced and non-resectable gastric cancer: A phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989; 7: 1318-25.
• 37. Plukker JT, Mulder NH, Sleijfer DT et al.: Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: Phase II study with methotrexate and 5-fluorouracil. Br J Surg 1991; 78: 995-1001.
• 38. Popiela T, Kulig J, Kolodziejcyk P et al.: 20 Jahre Erfahrung mit der multimodalen Behandlung von Patienten mit Magenkarzinom in Polen. Zentralbl Chir 2001; 126: 763-71.[Crossref]
• 39. Schuhmacher C, Schlag P, Lordick F et al.: Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. J Clin Oncol 2010; 28: 5210-5218.[Crossref]
• 40. Cunningham D, Allum WH, Stenning SP et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
• 41. Ychou M, Boige V, Pignon JP et al.: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: A FNLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-21.[Crossref]
• 42. Meyer H-J: The influence of case load and the extent of resection on the quality of treatment outcome in gastric cancer. Eur J Surg Oncol 2005; 31: 595-604.[PubMed][Crossref]
• 43. Siewert JR, Böttcher K, Stein HJ et al.: Relevant prognostic factors in gastric cancer. Ten-Year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-61.[PubMed][Crossref]
• 44. Napieralski R, Ott K, Kremer M et al.: Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: Relation to therapy response and clinicopathologic and molecular features. Clin Cancer Res 2007; 13: 5095- 5102.[Crossref][WoS]
• 45. Ott K, Vogelsang H, Mueller J et al.: Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatinbased chemotherapy in gastric carcinoma. Clin Cancer Res 2003; 9: 2307-15.
• 46. Weber WA , Ott K, Becker K et al.: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-65.[PubMed]
• 47. Lowy AM , Mansfield PF, Leach SD et al.: Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229: 303-08.[Crossref]
• 48. Ott K, Herrmann K, Lordick F et al.: Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long term results of a prospective study. Clin Cancer Res 2008; 14: 2012-18.[Crossref]
• 49. Becker K, Mueller JD, Schuhmacher C et al.: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98: 1521-30.[PubMed][Crossref]
• 50. Schuhmacher, C: Negative trial results are important to understand the mechanisms of multimodality therapy in gastric cancer. Gastric Cancer 2011; 14: 203-05.[PubMed][WoS]

Identifiers

DOI

10.2478/v10035-012-0079-z